Shire increases 2013 earnings forecast after strong Q3
LONDON Oct 24 (Reuters) - British drugmaker Shire raised its full-year earnings growth forecast on Thursday after lower-than-expected research and development costs helped it to beat forecasts for the third quarter.
The company, which makes drugs to treat hyperactivity and expensive medicines for rare disease, reported a 12 percent rise in revenue to $1.24 billion and earnings measured in non-GAAP EPS per ADS of $1.77, up 30 percent.
Analysts were expecting the company to report revenue of $1.2 billion and non-GAAP EPS per ADS of $1.63, according to a company-compiled poll of 20 brokers.
It said it now expected to deliver mid-to-high teens growth in Non GAAP earnings for 2013, up from double-digit growth it predicted in July.
Shares in Shire, which have risen by a third since the start of the year, hitting an all-time of 2,602 pence last month, extended earlier gains to trade up 5 percent at 2,655 pence at 1112 GMT on Thursday.
Trending On Reuters
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video